Ezetimibe is a lipid-lowering agent that inhibits the intestinal absorption of cholesterol and other related phytosterols. It is used alone or in combination with other lipid-lowering agents in the treatment of various forms of hypercholesterolemia. Since its FDA approval in 2002, there are no known citations of ezetimibe-induced pancreatitis.

We report a case of Crohn's disease that was associated with marked dermatologic manifestations depicting necrotizing vasculitis around the ankles. On further evaluation, this patient was found to have aortic narrowing, which fit the criteria for Takayasu's arteritis.

No abstract

No abstract